Major Depressive Disorder Clinical Trial
— JumpStepOfficial title:
Jump Step - A Participatory Approach to Physical Activity & Mental Wellness
The WHO, the Pan American Health Organization, the EU Council of Ministers, the World
Federation of Mental Health, and the UK Royal College of Psychiatrists all agree -"there can
be no health without mental health". Within Canada, 6.7M people live with a mental illness
and when family and caregivers are included almost everyone is affected.
A systematic review (2014) concluded that physical activity has a significant potential for
reducing depressive symptoms in people with a mental illness. Globally, physical inactivity
is "pandemic". Current guidelines recommend a minimum of only a 150 minutes a week of
moderately vigorous exercise but 85% of Canadians do not meet the national recommendations.
How then can people with depression be motivated to become physically more active?
Group Medical Visits (GMVs) can be used to provide health services and they have proven
effective in some settings, including mood disorders. As well as providing economic and
resource efficiencies, the GMV model has the potential to add a 'support
group/accountability' element for behavioural interventions such as physical activity
promotion; such influence is not present in an individual patient-physician consultation.
"Jump Step" is a 14-week program within a GMV setting designed to motivate and support
people with depression to engage in regular physical activity. The investigators seek to
design, implement, and evaluate the effectiveness of the Group Medical Visits focused on
promoting physical activity for patients with depression.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | June 2017 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
We will recruit up to 80 participants who Inclusion Criteria: - are adults (=18yrs) - have a confirmed psychiatric assessment of Major Depressive Disorder (MDD) and/or Bipolar II, depressive - are of moderate or higher severity (PHQ-9 >14) - are community-dwelling and able to attend Group Medical Visits in the Lower Mainland - are able to comply with scheduled visits, treatment plan, and other procedures; - read, write, and speak English with acceptable auditory and visual acuity - provide signed/dated informed consent; and - able to walk independently. Exclusion Criteria: - Active psychotic symptoms - a primary active diagnosis of substance abuse. Participants will need to have a working proficiency in English as group discussions, accompanying texts, and instructions will all be in English. To provide adequate translation services for these elements in one or more other languages is beyond our budget and may also influence the dynamics of the GMV. It could be considered in a future iteration of this research program. |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Centre for Hip Health & Mobility, Department of Family Practice | Vancouver | British Columbia |
Canada | Mood Disorders Association of BC | Vancouver | British Columbia |
Canada | Robert Lee YMCA | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | Mood Disorders Association of BC, Vancouver Foundation, YMCA |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | 'Jump Step Facilitators Questionnaire' | We will interview the Jump Step facilitators about their experience of the intervention. | Baseline | No |
Other | 'Jump Step Facilitators Questionnaire' | We will interview the Jump Step facilitators about their experience of the intervention. | Post-Intervention (14 weeks) | No |
Primary | 'Jump Step Intervention Questionnaire' | We will interview participants about physical activity levels, as well as their experience within the Jump Step intervention and its impact on their lives. We will also collect demographic data (age, gender, annual income, education level, self-identified disabilities, etc.) | Post-Intervention (14 weeks) | No |
Secondary | Physical Activity | We will measure participants' physical activity level (Actigraph; accelerometer). | Baseline | No |
Secondary | Physical Activity | We will measure participants' physical activity level (Actigraph; accelerometer). | Post-Intervention (14 weeks) | No |
Secondary | Patient Activation | a participants' levels of 'activation' | Baseline | No |
Secondary | Patient Activation | a participants' levels of 'activation' | Post-Intervention (14 weeks) | No |
Secondary | Anxiety | We will assess participants' anxiety ratings (GAD-7) | Baseline | No |
Secondary | Anxiety | We will assess participants' anxiety ratings (GAD-7) | Post-Intervention (14 weeks) | No |
Secondary | Social Support | We will assess participants' levels of social support (abridged Berlin Social Support Scales (BSSS)) | Baseline | No |
Secondary | Social Support | We will assess participants' levels of social support (abridged Berlin Social Support Scales (BSSS)) | Post-Intervention (14 weeks) | No |
Secondary | Depression | We will assess participants' depression ratings via the PHQ-9. | Baseline | No |
Secondary | Depression | We will assess participants' depression ratings via the PHQ-9. | Post-Intervention (14 weeks) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |